Cyclin D1 amplification occurred in about 5–8% of all HCC patients and 16–22% in breast cancer patients in TCGA databases (http://www.cbioportal.org/index.do, accessed on January 10, 2016). Here, CCND1 is linked to hepatocellular carcinoma.